Premium
Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A 2 /prostaglandin H 2 receptor in human platelets
Author(s) -
Swann Patrick G.,
Venton Duane L.,
Le Breton Guy C.
Publication year - 1989
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(89)80137-1
Subject(s) - thromboxane receptor , docosahexaenoic acid , eicosapentaenoic acid , thromboxane , thromboxane a2 , platelet , chemistry , platelet activation , prostaglandin h2 , thromboxane a synthase , pharmacology , receptor , thromboxane b2 , biochemistry , medicine , fatty acid , biology , polyunsaturated fatty acid
The present study investigated the mechanism by which eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) inhibit platelet activation induced by thromboxane A 2 . DHA was found to be more potent than EPA in blocking platelet aggregation induced by the stable thromboxane A 2 mimetic, U46619. Furthermore, this inhibition by DHA or EPA was competitive. Binding studies using 3 H‐U46619 demonstrated that both EPA and DHA interact with the platelet thromboxane receptor. The potency of the inhibition of binding corresponded with that seen for the inhibition of aggregation. These results suggest that thromboxane receptor antagonism may be an important mechanism by which EPA and DHA modulate platelet reactivity in vivo.